134 MinamiT.SakitaY.IchidaS.DohiY
Product Inquiry [email protected]
Authors relationships and activities CM serves or has served on the advisory panel for Novo Nordisk, Sanofi, Eli Lilly and Company, Novartis, Dexcom, Boehringer Ingelheim, Bayer, Roche, Abbott, Medtronic, Insulet Biomea Fusion, SAB Bio, vTv Therapeutics and Vertex
We only blend in cGMP, NSF certified and FDA-registered facilities, testing in 3 rounds for purity and potency.
Higher values are associated with: Impaired liver metabolism and fatty liver disease Poor glucose control and worsening insulin resistance Increased cardiovascular and stroke risk Chronic low-grade inflammation Even normal weight individuals may show elevated visceral fat on InBody analysis, revealing a hidden metabolic risk that BMI cannot detect
Systematic documentation of adverse effects is crucial for optimising GLP-1 therapy and ensuring patient safety